SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Steen Karin)
 

Sökning: WFRF:(Steen Karin) > (2015-2019) > Chemotherapy-Free I...

  • Lockmer, SandraKarolinska Institutet (författare)

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity : Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • 2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-372711
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372711URI
  • https://doi.org/10.1200/JCO.18.00262DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:139712467URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Purpose: For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients were treated first line with a rituximab-containing regimen without chemotherapy. The purpose of this study was to assess long-term survival, risk of transformation, and need of new therapies.Methods: Data were collected at cross-sectional follow-up for 321 patients with indolent lymphoma (84% with follicular lymphomas [FL]) included in one of two Nordic Lymphoma Group trials (accrual 1998 to 1999 and 2002 to 2008). All patients received first-line therapy with one or two cycles of four weekly infusions of rituximab 375 mg/m(2), and 148 were randomly allocated to the addition of interferon alfa-2a. Follow-up data were retrieved from initial trial databases and medical records on repeated clinical evaluations.Results: At the end of follow-up, 73% of patients were alive, with a median follow-up after random assignment of 10.6 years. Among all, 36% (38% with FL) had never needed chemotherapy. For patients with FL who required new therapy within 24 months because of early disease progression, the 10-year survival rate was 59% versus 81% for those with longer remission. Interferon was not shown to improve long-term outcome. Transformation was diagnosed in 20% of all patients (2.4% per person-year) and in 18% with FL. An additional malignancy was found in 12%.Conclusion: Approximately one third of patients with symptomatic indolent lymphoma (30% with FL, 23% without FL) did not need new therapy in the long term after first-line rituximab without chemotherapy. In the entire cohort, 10-year survival was excellent with no major safety issues, which suggests that chemotherapy can be delayed safely in the majority of patients.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Ostenstad, BjornOslo Univ Hosp, Oslo, Norway (författare)
  • Hagberg, HansUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)hanshagb (författare)
  • Holte, HaraldOslo Univ Hosp, Oslo, Norway (författare)
  • Johansson, Ann-SofieNorrlands Univ Hosp, Umea, Sweden (författare)
  • Wahlin, Bjorn EngelbrektKarolinska Institutet (författare)
  • Wader, Karin FahlSt Olavs Hosp, Trondheim, Norway (författare)
  • Steen, Chloe BeateUniv Oslo, Oslo, Norway (författare)
  • Meyer, PeterStavanger Univ Hosp, Stavanger, Norway (författare)
  • Maisenholder, MartinUniv Hosp Northern Norway, Tromso, Norway (författare)
  • Smedby, Karin EkstromKarolinska Institutet (författare)
  • Brown, PeterRigshosp, Copenhagen, Denmark (författare)
  • Kimby, EvaKarolinska Institutet (författare)
  • Karolinska InstitutetOslo Univ Hosp, Oslo, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Oncology36:33, s. 3315-33230732-183X1527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy